Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(50%)

Phase Distribution

Ph phase_1
3
75%
Ph phase_2
1
25%

Phase Distribution

3

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Terminated(2)
Other(2)

Detailed Status

unknown2
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (75.0%)
Phase 21 (25.0%)

Trials by Status

unknown250%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

NCT05226533
terminatedphase_1

To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

NCT04541485
unknownphase_1

To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003

NCT04592835
unknownphase_1

To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19

NCT04524052

Clinical Trials (4)

Showing 4 of 4 trials
NCT05226533Phase 2

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

Terminated
NCT04541485Phase 1

To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines)

Terminated
NCT04592835Phase 1

To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003

Unknown
NCT04524052Phase 1

To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4